--- title: "Bicycle Therapeutics | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 2.92 M" type: "news" locale: "en" url: "https://longbridge.com/en/news/252215683.md" published_at: "2025-08-08T11:15:41.000Z" --- # Bicycle Therapeutics | 10-Q: FY2025 Q2 Revenue Misses Estimate at USD 2.92 M Revenue: As of FY2025 Q2, the actual value is USD 2.92 M, missing the estimate of USD 9.429 M. EPS: As of FY2025 Q2, the actual value is USD -1.14, missing the estimate of USD -0.9582. EBIT: As of FY2025 Q2, the actual value is USD -79.18 M, missing the estimate of USD -70.9 M. ### Segment Revenue - **Collaboration Revenue**: $2.9 million for the three months ended June 30, 2025, compared to $9.4 million for the same period in 2024. For the six months ended June 30, 2025, collaboration revenue was $12.9 million, down from $28.9 million in 2024. ### Operational Metrics - **Net Loss**: $78.9 million for the three months ended June 30, 2025, compared to $39.8 million for the same period in 2024. For the six months ended June 30, 2025, net loss was $139.7 million, compared to $66.4 million in 2024. - **Research and Development Expenses**: $71.0 million for the three months ended June 30, 2025, compared to $40.1 million for the same period in 2024. For the six months ended June 30, 2025, R&D expenses were $130.1 million, compared to $74.9 million in 2024. - **General and Administrative Expenses**: $18.5 million for the three months ended June 30, 2025, compared to $15.9 million for the same period in 2024. For the six months ended June 30, 2025, G&A expenses were $39.6 million, compared to $32.3 million in 2024. ### Cash Flow - **Net Cash Used in Operating Activities**: $159.2 million for the six months ended June 30, 2025, compared to $115.5 million for the same period in 2024. - **Net Cash Used in Investing Activities**: $1.1 million for the six months ended June 30, 2025, compared to $0.4 million in 2024. - **Net Cash (Used in) Provided by Financing Activities**: - $0.1 million for the six months ended June 30, 2025, compared to $551.5 million in 2024. ### Future Outlook and Strategy - **Core Business Focus**: Bicycle Therapeutics plc plans to continue the development of its product candidates, including zelenectide pevedotin, BT5528, and BT7480, with ongoing clinical trials and preclinical activities. The company expects to incur significant expenses as it advances these programs and builds its commercial capabilities. - **Non-Core Business**: The company announced cost reduction initiatives expected to reduce planned operating costs by approximately 30% over the course of its expected financial runway period, primarily through a workforce reduction of approximately 25%. ### Related Stocks - [BCYC.US - Bicycle Therapeutics](https://longbridge.com/en/quote/BCYC.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Bicycle Therapeutics plc 为首席财务官 Travis Thompson 制定了新的薪酬方案 | Bicycle Therapeutics plc 宣布其新任首席财务官 Travis Thompson 的年基本工资为 500,000 美元，并将从 2026 年 1 月 29 日起获得相当于其基本工资 50% 的年度目标奖金。此外，Tho | [Link](https://longbridge.com/en/news/274652142.md) | | Bicycle Therapeutics 宣布领导层变动，并任命新的董事会成员 | Bicycle Therapeutics plc 宣布了几项管理层变动。Travis Thompson 被任命为新的首席财务官，接替 Alethia Young。Michael Method 将接任首席医学官，替换 Eric Westin。 | [Link](https://longbridge.com/en/news/274651009.md) | | Bicycle Therapeutics 在新的公司演示中展示了创新的精准导向癌症疗法 | Bicycle Therapeutics plc 发布了一份企业演示文稿，详细介绍了其在开发 Bicycle® 分子用于精准导向癌症疗法方面的进展。演示文稿强调了肿瘤学项目的进展，包括在转移性尿路上皮癌中 zelenectide peved | [Link](https://longbridge.com/en/news/272266761.md) | | Bicycle Therapeutics（NASDAQ:BCYC）的首席运营官 Alistair Milnes 出售了 3,244 股股票 | Bicycle Therapeutics 首席运营官 Alistair Milnes 以每股 6.80 美元的价格出售了 3,244 股，总计 22,059.20 美元，减少了 2.26% 的持股，现持有 140,133 股，价值 952, | [Link](https://longbridge.com/en/news/271729019.md) | | 首席财务官 Alethia Young 报告出售了 Bicycle Therapeutics plc 的普通股 | Alethia Young，Bicycle Therapeutics plc 的首席财务官，报告了该公司普通股的处置。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供参考，不应被视为财务、投资或法律建议。原始内容于 2026 | [Link](https://longbridge.com/en/news/271716698.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.